Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions
Related Experiment Video
Updated: Feb 7, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Melissa D Klein1, Craig R Lee2,3,4, George A Stouffer1,2
1Division of Cardiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Abstract:
It is well established that the CYP2C19 nonfunctional *2 and *3 polymorphisms impair the bioactivation and antiplatelet effects of clopidogrel, and increase the risk of adverse cardiovascular events following percutaneous coronary intervention. In contrast, CYP2C19 genotype does not impact clinical response to prasugrel or ticagrelor. Recent studies have evaluated the impact of CYP2C19 genotype-guided selection of antiplatelet therapy on clinical outcomes and begun to close some of the gaps in knowledge and uncertainty that have impeded widespread clinical implementation of this precision medicine approach. This review will critically evaluate recent data and offer new insight into the potential clinical utility of genotype-guided antiplatelet therapy in the context of current clinical practice guidelines.
Insights
CYP2C19 genotype affects clopidogrel response but not prasugrel or ticagrelor. Genotype-guided antiplatelet therapy shows promise for precision cardiovascular medicine, addressing implementation gaps.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Precision Medicine
Background:
- CYP2C19 nonfunctional *2 and *3 polymorphisms reduce clopidogrel's effectiveness.
- This impairment increases cardiovascular event risk after percutaneous coronary intervention.
- CYP2C19 genotype does not affect prasugrel or ticagrelor response.
Purpose of the Study:
- To review recent data on CYP2C19 genotype-guided antiplatelet therapy.
- To provide insight into the clinical utility of this precision medicine approach.
- To address knowledge gaps impeding widespread implementation.
Main Methods:
- Critical evaluation of recent studies.
- Analysis of clinical outcomes data.
- Review of current clinical practice guidelines.
Main Results:
- Recent studies are evaluating the impact of CYP2C19 genotype-guided antiplatelet selection on clinical outcomes.
- Data is beginning to clarify the clinical utility of this approach.
- Uncertainty regarding implementation is decreasing.
Conclusions:
- CYP2C19 genotype is a critical factor for clopidogrel efficacy.
- Prasugrel and ticagrelor offer alternative antiplatelet options independent of CYP2C19 genotype.
- Genotype-guided antiplatelet therapy represents a significant advancement in precision cardiovascular medicine.
Related Concept Videos
The Evidence for Evolution
Predicting Reaction Outcomes
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Gene Therapy
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

